Correlation Between Machine Learning-based Characterization of HER2 Protein Expression by Immunohistochemistry and Response to Neoadjuvant Treatment in HER2+Breast Cancer

被引：0
|
作者：
Kurt, Busem Binboga [1 ]
Kirkup, Christian [2 ]
Ogayo, Esther Ritah [1 ]
Krause, Emma [2 ]
Cramer, Harry [1 ]
Degryse, Sandrine [2 ]
Hennek, Stephanie [2 ]
Rahman, Tasnim [1 ]
Tarantino, Paolo [1 ]
Chambre, Laura [2 ]
Trotter, Ben [2 ]
Hipp, Jennifer [2 ]
Drage, Michael [2 ]
Tolaney, Sara [1 ]
Schnitt, Stuart [3 ]
Waks, Adrienne [1 ]
Mittendorf, Elizabeth [4 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] PathAI, Boston, MA USA
[3] Harvard Med Sch, Dana Farber Canc Inst, Brigham & Womens Hosp, Boston, MA USA
[4] Dana Farber Canc Inst, Brigham & Womens Canc Ctr, Boston, MA USA
来源：
LABORATORY INVESTIGATION | 2024年 / 104卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
102
引用
收藏
页码：S121 / S123
页数：3
相关论文
共 50 条
  • [21] Loss of HER2 after neoadjuvant treatment of HER2+early breast cancer
    Morales, S.
    Gasol Cudos, A.
    Rodriguez Galindo, A.
    Velasco, A.
    Canosa Morales, C.
    Sanchez Guzman, D. -R.
    Mele Olive, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S51 - S51
  • [22] The association of higher tumor HER2 load with treatment response to neoadjuvant therapy in HER2 positive breast cancer patients
    Lillemoe, T. J.
    Susnik, B.
    Grimm, E.
    Kang, S-H L.
    Swenson, K. K.
    Krueger, J. L.
    Finkelstein, M. J.
    Tsai, M. L.
    CANCER RESEARCH, 2017, 77
  • [23] HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer
    Yao, L.
    Liu, Y.
    Li, Z.
    Ouyang, T.
    Li, J.
    Wang, T.
    Fan, Z.
    Fan, T.
    Lin, B.
    Xie, Y.
    ANNALS OF ONCOLOGY, 2011, 22 (06) : 1326 - 1331
  • [24] Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
    Atallah, N. M.
    Alsaleem, M.
    Toss, M. S.
    Mongan, N. P.
    Rakha, E.
    BRITISH JOURNAL OF CANCER, 2023, 129 (10) : 1692 - 1705
  • [25] Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
    N. M. Atallah
    M. Alsaleem
    M. S. Toss
    N. P. Mongan
    E. Rakha
    British Journal of Cancer, 2023, 129 : 1692 - 1705
  • [26] Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer
    Chen, Hai-Long
    Chen, Qiang
    Deng, Yong-Chuan
    MEDICINE, 2021, 100 (44)
  • [27] Relationship between survival to breast cancer and level of HER2 expression by immunohistochemistry.
    Provencher, Louise
    Diorio, Caroline
    Desbiens, Christine
    Poirier, Brigitte
    Poirier, Eric
    Boudreau, Dominique
    Doyle, Catherine
    Popa, Ion
    Gagne, Isabelle
    Hogue, Jean-Charles
    Lemieux, Julie
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+breast cancer
    Green, Andrew R.
    Barros, Fabricio F. T.
    Abdel-Fatah, Tarek M. A.
    Moseley, Paul
    Nolan, Christopher C.
    Durham, Alice C.
    Rakha, Emad A.
    Chan, Stephen
    Ellis, Ian O.
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 145 (01) : 33 - 44
  • [29] Deep learning trained on hematoxylin and eosin tumor region of Interest predicts HER2 status and trastuzumab treatment response in HER2+breast cancer
    Farahmand, Saman
    Fernandez, Aileen, I
    Ahmed, Fahad Shabbir
    Rimm, David L.
    Chuang, Jeffrey H.
    Reisenbichler, Emily
    Zarringhalam, Kourosh
    MODERN PATHOLOGY, 2022, 35 (01) : 44 - 51
  • [30] HER2 classification in breast cancer cells: A new explainable machine learning application for immunohistochemistry
    Cordova, Claudio
    Munoz, Roberto
    Olivares, Rodrigo
    Minonzio, Jean-Gabriel
    Lozano, Carlo
    Gonzalez, Paulina
    Marchant, Ivanny
    Gonzalez-Arriagada, Wilfredo
    Olivero, Pablo
    ONCOLOGY LETTERS, 2023, 25 (02)
12345